Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.57 |
| ▸ | CTNNB1 | P35222 | 18/20 | 0.56 |
| ▸ | TCF7L2 | Q9NQB0 | 18/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4173478 | 0.86 | CTNNB1 (0.74) | CTNNB1TCF7L2 | |
| SCHEMBL4171599 | 0.86 | CTNNB1 (0.76) | CTNNB1TCF7L2 | |
| SCHEMBL2256396 | 0.76 | CTNNB1 (0.55) | PDE5ACTNNB1TCF7L2 | |
| SCHEMBL25277062 | 0.74 | ALDH1A1 (0.79) | — | |
| SCHEMBL4175985 | 0.73 | CTNNB1 (0.80) | CTNNB1TCF7L2 | |
| SCHEMBL7287561 | 0.73 | PDE5A (1.00) | PDE5A | |
| SCHEMBL4166680 | 0.72 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL4170114 | 0.72 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL4173423 | 0.72 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL4175344 | 0.72 | CTNNB1 (1.00) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | claimed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | claimed |
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | PDE5A 3490/4885CTNNB1 2/4885TCF7L2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.